Navigation Links
BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
Date:11/28/2011

NOVATO, Calif., Nov. 28, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the manufacturing facility expansion in Novato, CA.  The facility will support up to $1.0 billion in revenue for BioMarin's growing enzyme replacement therapy portfolio, which is comprised of complex glycoprotein products produced by mammalian cells.  

"We are pleased with this first cycle approval of our manufacturing facility expansion which reflects our effective interactions with regulatory authorities and the high caliber of our technical operations team," stated Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "BioMarin has a strong track record in manufacturing enzyme replacement therapies.  The approval of this facility supports the manufacturing requirements for anticipated peak sales of our commercial products and also supports several of our clinical and pre-clinical programs.  BioMarin's Novato manufacturing facilities are also producing clinical trial material for our pipeline protein products including, GALNS for MPS IV, PEG-PAL for PKU, our CNP analog for Achondroplasia and a new biologic to be disclosed at our upcoming R&D Day."

Mr. Bienaime continued, "The facility expansion will also be the initial site of commercial production for GALNS for MPS IVA, if pivotal Phase 3 results are positive in the second half of 2012. The next phase in our manufacturing capabilities expansion will occur in our recently purchased facility in Ireland.  Commercial production for some of our products in Ireland, including GALNS, will provide additional manufacturing diversity and assure adequate capacity for commercial demand of our current and future products."

The multi-product manufacturing plant in Novato was first licensed for pro
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioMarin to Host a Research and Development Day on December 8th
2. BioMarin Announces Third Quarter 2011 Financial Results
3. BioMarin to Present at the UBS Global Life Sciences Conference
4. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
5. BioMarin to Present at the Baird Health Care Conference
6. BioMarin to Present at the Wedbush Life Sciences Conference
7. BioMarin Announces Second Quarter 2011 Financial Results
8. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
9. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
10. BioMarin to Present at the William Blair Growth Stock Conference
11. BioMarin to Present at the Jefferies Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... N.Y. , Oct. 20, 2014 Pharmaceutic ... outsourcing facility in Albany, NY ... trials. The company meets and/or exceeds the FDA standards ... and 21 CFR Part 211. The ... the highest levels of quality assurance and quality control. ...
(Date:10/20/2014)... -- Norgine B.V. today announced that the ... preparation, NER1006, presented at the 79 th Annual ... Philadelphia, PA , has met its ... endpoint of cleansing success. The study demonstrated high quality ... in screening colonoscopy patients. [1] (Logo: ...
(Date:10/19/2014)... , October 20, 2014 Shire plc (LSE: ... , Interim Chief Financial Officer (CFO), has notified the Board of ... to pursue a new career opportunity as CFO of Severn Trent ... and the company will commence a search for a new CFO ... "James has helped build and lead a high-quality finance team ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... Dec. 22, 2010 SCOLR Pharma, Inc., a Delaware corporation ... it notified the NYSE Amex Exchange (the "Exchange") of its ... Exchange Commission (the "Commission") to effect the voluntary withdrawal of ... to file the Form 25 with the Commission on or ...
... WPI ) today announced the U.S. Food and ... – the first and only low dose oral contraceptive to ... chewable form, with four 75 mg ferrous fumarate (iron) placebo ... proven effective in lowering the risk of pregnancy. ...
Cached Medicine Technology:SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange 2SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange 3SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange 4Watson Announces Novel Oral Contraceptive Approval 2Watson Announces Novel Oral Contraceptive Approval 3Watson Announces Novel Oral Contraceptive Approval 4
(Date:10/20/2014)... October 20, 2014 Allegheny General Hospital’s ... that enables physicians to repair a damaged mitral valve ... MitraClip system, developed by Abbott Vascular , ... progressive and life-threatening condition in which the heart’s mitral ... flow backward from the heart’s left ventricle into the ...
(Date:10/20/2014)... hc1.com today announced the launch ... that enables healthcare organizations of all sizes to ... relationship management (“CRM”) solution. , Designed from the ... the healthcare industry, the hc1 Healthcare Relationship Cloud™ ... by combining healthcare CRM, HIPAA-compliant collaboration, and real-time ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update ... FDA on Sit and Slim II . , ... or use Sit and Slim II because it contains ... as weight loss product on various websites and possibly in ... 2010 for safety reasons, can significantly increase blood pressure and/or ...
(Date:10/20/2014)... October 20, 2014 National Teen Driver Safety ... the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) ... encouraging parents of teen drivers to talk to their teens ... , Motor vehicle crashes are the leading cause of death ... involved in fatal crashes, and 859 (42%) of those teen ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... (NYSE:,NTY) (http://www.NBTY.com ), a leading global manufacturer and ... cast the,presentation by Harvey Kamil, President and Chief Financial ... in New York on Wednesday,September 17, 2008., The ... NBTY,s web site, (http://www.nbty.com ) on Wednesday, September 17, ...
... Calif., Sept. 11 Abaxis, Inc.,(Nasdaq: ABAX ), ... today that Clint Severson, CEO and,President, will present at ... 17, 2008 at 8:00 a.m. EDT, at the Omni ... Abaxis develops, manufactures and markets portable blood analysis,systems ...
... Kurian, MD, and her colleagues at the Stanford University ... identify women who might have dangerous genetic mutations that ... well for white women. But they seemed to be ... repeatedly surprised when Asian women who the models predicted ...
... Wolters Kluwer Health, a,division of Wolters Kluwer, ... for students, professionals, and institutions in medicine,nursing, ... announced,today the appointment of Scott Lubeck Vice ... Lubeck comes to Wolters Kluwer Health ...
... Sept. 11 Vasculitis,Foundation (VF), the leading organization ... all types of vasculitis, is taking,its advocacy and ... of its,first-ever webinar, Monday, September 22, 12:30 - ... easily accessible information about,vasculitis to the medical community ...
... newly-developed technology at the Delft University of Technology in the ... be a thing of the past. This is the message ... Institute Delft (RID) in an article in university journal ... hospitals are facing a shortage of radio isotopes which means ...
Cached Medicine News:Health News:NBTY to Web Cast Presentation at CL King Best Ideas Conference 2Health News:Risk of breast cancer mutations underestimated for Asian women, Stanford study shows 2Health News:Risk of breast cancer mutations underestimated for Asian women, Stanford study shows 3Health News:Wolters Kluwer Health Appoints Scott Lubeck Vice President, Technology of its Professional & Education Unit 2Health News:Vasculitis Foundation Integrates Education, Outreach and Technology in First-Ever Webinar on Potentially Life-Threatening Disease 2Health News:Delft University of Technology patent for manufacturing radio isotopes 2
Marquette General Health System Reference Laboratory provides a full range of testing including, Chemistry, Hematology, Coagulation, Urinalysis, Microbiology, Cytology, Anatomic Pathology, Flow Cytom...
... The Johns Hopkins University Dermatology, ... Laboratory is a federally-(Clinical Laboratory Improvement ... that began operation in 1982. Its ... quality diagnostic allergy and immunology testing ...
... national reference laboratory and a laboratory ... an extensive test menu of highly ... clinical and anatomic pathology. Owned by ... clients include university teaching hospitals and ...
Sharp tipped scissors angled 135 from the shaft with a horizontal cutting action. For cutting in the plane parallel to the retina and cutting membranes adherent to the retinal surface (delamination)....
Medicine Products: